These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 31877423)

  • 21. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats.
    Mairesse J; Silletti V; Laloux C; Zuena AR; Giovine A; Consolazione M; van Camp G; Malagodi M; Gaetani S; Cianci S; Catalani A; Mennuni G; Mazzetta A; van Reeth O; Gabriel C; Mocaër E; Nicoletti F; Morley-Fletcher S; Maccari S
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):323-38. PubMed ID: 22310059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sleep and obsessive-compulsive disorder (OCD).
    Paterson JL; Reynolds AC; Ferguson SA; Dawson D
    Sleep Med Rev; 2013 Dec; 17(6):465-74. PubMed ID: 23499210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series.
    Fornaro M
    Ann Gen Psychiatry; 2011 Feb; 10(1):5. PubMed ID: 21356085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eveningness is associated with poor sleep quality and negative affect in obsessive-compulsive disorder.
    Simor P; Harsányi A; Csigó K; Miklós G; Lázár AS; Demeter G
    J Behav Addict; 2018 Mar; 7(1):10-20. PubMed ID: 29415552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
    San L; Arranz B
    Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circadian zeitgebers and treatment outcome in inpatient programs for obsessive compulsive disorder (OCD): a pilot study.
    Coles ME; Stewart E
    Chronobiol Int; 2019 Sep; 36(9):1190-1193. PubMed ID: 31198055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam.
    Bhutada P; Dixit P; Thakur K; Deshmukh P; Kaulaskar S
    Kaohsiung J Med Sci; 2013 Jul; 29(7):362-7. PubMed ID: 23768699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light.
    Tchekalarova J; Stoynova T; Ilieva K; Mitreva R; Atanasova M
    Pharmacol Biochem Behav; 2018 Aug; 171():1-9. PubMed ID: 29807067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review.
    Pompili M; Serafini G; Innamorati M; Venturini P; Fusar-Poli P; Sher L; Amore M; Girardi P
    World J Biol Psychiatry; 2013 Aug; 14(6):412-31. PubMed ID: 23530731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.
    De Berardis D; Marini S; Fornaro M; Srinivasan V; Iasevoli F; Tomasetti C; Valchera A; Perna G; Quera-Salva MA; Martinotti G; di Giannantonio M
    Int J Mol Sci; 2013 Jun; 14(6):12458-83. PubMed ID: 23765220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Agomelatine: innovative pharmacological approach in depression.
    Popoli M
    CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties.
    Stahl SM
    CNS Spectr; 2014 Jun; 19(3):207-12. PubMed ID: 24901504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed sleep phase in severe obsessive-compulsive disorder: a systematic case-report survey.
    Mukhopadhyay S; Fineberg NA; Drummond LM; Turner J; White S; Wulff K; Ghodse H
    CNS Spectr; 2008 May; 13(5):406-13. PubMed ID: 18496478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agomelatine in the treatment of seasonal affective disorder.
    Pjrek E; Winkler D; Konstantinidis A; Willeit M; Praschak-Rieder N; Kasper S
    Psychopharmacology (Berl); 2007 Mar; 190(4):575-9. PubMed ID: 17171557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine.
    Pringle A; Bogdanovskaya M; Waskett P; Zacharia S; Cowen PJ; Harmer CJ
    J Psychopharmacol; 2015 Oct; 29(10):1129-32. PubMed ID: 26174133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical effectiveness, cost-effectiveness and acceptability of low-intensity interventions in the management of obsessive-compulsive disorder: the Obsessive-Compulsive Treatment Efficacy randomised controlled Trial (OCTET).
    Lovell K; Bower P; Gellatly J; Byford S; Bee P; McMillan D; Arundel C; Gilbody S; Gega L; Hardy G; Reynolds S; Barkham M; Mottram P; Lidbetter N; Pedley R; Molle J; Peckham E; Knopp-Hoffer J; Price O; Connell J; Heslin M; Foley C; Plummer F; Roberts C
    Health Technol Assess; 2017 Jun; 21(37):1-132. PubMed ID: 28681717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.
    Fornaro M; Prestia D; Colicchio S; Perugi G
    Curr Neuropharmacol; 2010 Sep; 8(3):287-304. PubMed ID: 21358978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parental obsessive-compulsive disorder as a prognostic factor in a year long fluvoxamine treatment in childhood and adolescent obsessive-compulsive disorder.
    Yaryura-Tobias JA; Grunes MS; Walz J; Neziroglu F
    Int Clin Psychopharmacol; 2000 May; 15(3):163-8. PubMed ID: 10870874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delayed bedtimes and obsessive-compulsive symptoms.
    Coles ME; Schubert JR; Sharkey KM
    Behav Sleep Med; 2012 Oct; 10(4):258-65. PubMed ID: 22946735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sleep disturbances in obsessive-compulsive disorder: Association with non-response to repetitive transcranial magnetic stimulation (rTMS).
    Donse L; Sack AT; Fitzgerald PB; Arns M
    J Anxiety Disord; 2017 Jun; 49():31-39. PubMed ID: 28388457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.